Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dermata Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dermata Therapeutics's regulatory disclosures and financial reporting.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 672,134 shares of Dermata Therapeutics, representing 9.99% of the class. The filing states Armistice Capital acts as investment manager to a Master Fund that directly holds the shares and that Armistice and Mr. Boyd share voting and dispositive power over those shares. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement. The filing affirms the position is held in the ordinary course of business and not for the purpose of changing control.
Dermata Therapeutics, Inc. reported unaudited second-quarter financials showing total assets of $6.64 million and cash and cash equivalents of $6.48 million as of June 30, 2025, which the company says will fund operations into the second quarter of 2026. The company recorded a net loss of $4.0 million for the six months ended June 30, 2025, and had an accumulated deficit of $69.7 million. Equity financing activity in early 2025 provided material cash inflows, including net proceeds of approximately $5.7 million from a warrant inducement and approximately $2.2 million from a January 2025 PIPE.
Clinical update: Dermata announced that its XYNGARI(TM) Phase 3 STAR-1 trial met all co-primary endpoints at week 12, with inflammatory lesion reductions of -16.8 versus -13.1 for placebo, noninflammatory lesion reductions of -17.3 versus -12.4 for placebo, and IGA responder rates of 29.4% versus 15.2% for placebo. Management notes a second Phase 3 trial (STAR-2) is required by the FDA. The company also discloses supply concentration risk (a Russian supplier) and Nasdaq minimum bid non-compliance with an exception period granted through August 14, 2025, creating ongoing listing risk.
On August 13, 2025 Dermata Therapeutics, Inc. submitted a Current Report on Form 8-K to furnish a press release that provides a corporate update and reports second quarter 2025 financial results for the quarter ended June 30, 2025. The filing identifies the press release as Exhibit 99.1 and an Interactive XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not "filed," and therefore is not subject to Section 18 liability or automatically incorporated by reference into future filings. The report is signed by CEO Gerald T. Proehl.